Elicio Therapeutics (NASDAQ:ELTX) & Cardiff Oncology (NASDAQ:CRDF) Financial Comparison

Cardiff Oncology (NASDAQ:CRDF) and Elicio Therapeutics (NASDAQ:ELTX) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.

Analyst Ratings

This is a summary of recent recommendations for Cardiff Oncology and Elicio Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiff Oncology	1	4	2	0	2.14
Elicio Therapeutics	1	1	4	0	2.50

Cardiff Oncology currently has a consensus target price of $7.50, suggesting a potential upside of 662.97%. Elicio Therapeutics has a consensus target price of $19.75, suggesting a potential upside of 543.32%. Given Cardiff Oncology’s higher probable upside, research analysts plainly believe Cardiff Oncology is more favorable than Elicio Therapeutics.

Profitability

This table compares Cardiff Oncology and Elicio Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cardiff Oncology	-7,885.43%	-93.24%	-68.74%
Elicio Therapeutics	N/A	-2,748.16%	-151.12%

Volatility & Risk

Cardiff Oncology has a beta of 1.49, indicating that its share price is 49% more volatile than the S&P 500. Comparatively, Elicio Therapeutics has a beta of 1.3, indicating that its share price is 30% more volatile than the S&P 500.

Valuation & Earnings

This table compares Cardiff Oncology and Elicio Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiff Oncology	$590,000.00	129.61	-$45.85 million	($0.67)	-1.47
Elicio Therapeutics	N/A	N/A	-$39.57 million	($2.40)	-1.28

Elicio Therapeutics has lower revenue, but higher earnings than Cardiff Oncology. Cardiff Oncology is trading at a lower price-to-earnings ratio than Elicio Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

16.3% of Cardiff Oncology shares are owned by institutional investors. Comparatively, 35.0% of Elicio Therapeutics shares are owned by institutional investors. 8.5% of Cardiff Oncology shares are owned by insiders. Comparatively, 50.9% of Elicio Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Elicio Therapeutics beats Cardiff Oncology on 7 of the 13 factors compared between the two stocks.

About Cardiff Oncology

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

About Elicio Therapeutics

Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.